Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes

IF 11.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Clinical Gastroenterology and Hepatology Pub Date : 2024-05-15 DOI:10.1016/j.cgh.2024.04.038
Trevor S. Barlowe , Chelsea Anderson , Robert S. Sandler , Disha Subramaniam , Alicia Muratore , John B. Buse , Lindsey N. Gouker , Rajiv T. Majithia , Nicholas J. Shaheen , Til Stürmer , Michael K. Dougherty
{"title":"Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes","authors":"Trevor S. Barlowe ,&nbsp;Chelsea Anderson ,&nbsp;Robert S. Sandler ,&nbsp;Disha Subramaniam ,&nbsp;Alicia Muratore ,&nbsp;John B. Buse ,&nbsp;Lindsey N. Gouker ,&nbsp;Rajiv T. Majithia ,&nbsp;Nicholas J. Shaheen ,&nbsp;Til Stürmer ,&nbsp;Michael K. Dougherty","doi":"10.1016/j.cgh.2024.04.038","DOIUrl":null,"url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Glucagon-like peptide-1–receptor agonists (GLP1-RAs) have been associated with greater retention of gastric contents, however, there is minimal controlled, population-based data evaluating the potential adverse effects<span> of GLP1-RA in the periprocedural setting. We aimed to determine if there is increased risk of aspiration and aspiration-related complications after upper endoscopy in patients using GLP1-RAs.</span></div></div><div><h3>Methods</h3><div><span>We used a nationwide commercial administrative claims database to conduct a retrospective cohort study<span> of patients aged 18 to 64 with type 2 diabetes who underwent outpatient upper endoscopy from 2005 to 2021. We identified 6,806,046 unique upper endoscopy procedures. We compared claims for aspiration and associated pulmonary adverse events in the 14 days after upper endoscopy between users of GLP1-RAs, </span></span>dipeptidyl peptidase 4 inhibitors<span><span><span> (DPP4is), and chronic opioids. We adjusted for age, sex, Charlson Comorbidity score, underlying </span>respiratory disease, and </span>gastroparesis.</span></div></div><div><h3>Results</h3><div>We found that pulmonary adverse events after upper endoscopy are rare, ranging from 6 to 25 events per 10,000 procedures. When comparing GLP1-RAs with DPP4i, crude relative risks of aspiration (0.67; 95% CI, 0.25–1.75), aspiration pneumonia<span> (0.95; 95% CI, 0.40–2.29), pneumonia (1.07; 95% CI, 0.62–1.86), or respiratory failure (0.75; 95% CI, 0.38–1.48) were not higher in patients prescribed a GLP1-RA. When comparing GLP1-RAs with opioids, crude relative risks were 0.42 (95% CI, 0.15–1.16) for aspiration, 0.60 (95% CI, 0.24–1.52) for aspiration pneumonia, 0.30 (95% CI, 0.19–0.49) for pneumonia, and 0.24 (95% CI, 0.13–0.45) for respiratory failure. These results were consistent across several sensitivity analyses.</span></div></div><div><h3>Conclusions</h3><div>GLP1-RA use is not associated with an increased risk of pulmonary complications after upper endoscopy compared with DPP4i use in patients with type 2 diabetes.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"23 5","pages":"Pages 739-747"},"PeriodicalIF":11.6000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1542356524004531","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & Aims

Glucagon-like peptide-1–receptor agonists (GLP1-RAs) have been associated with greater retention of gastric contents, however, there is minimal controlled, population-based data evaluating the potential adverse effects of GLP1-RA in the periprocedural setting. We aimed to determine if there is increased risk of aspiration and aspiration-related complications after upper endoscopy in patients using GLP1-RAs.

Methods

We used a nationwide commercial administrative claims database to conduct a retrospective cohort study of patients aged 18 to 64 with type 2 diabetes who underwent outpatient upper endoscopy from 2005 to 2021. We identified 6,806,046 unique upper endoscopy procedures. We compared claims for aspiration and associated pulmonary adverse events in the 14 days after upper endoscopy between users of GLP1-RAs, dipeptidyl peptidase 4 inhibitors (DPP4is), and chronic opioids. We adjusted for age, sex, Charlson Comorbidity score, underlying respiratory disease, and gastroparesis.

Results

We found that pulmonary adverse events after upper endoscopy are rare, ranging from 6 to 25 events per 10,000 procedures. When comparing GLP1-RAs with DPP4i, crude relative risks of aspiration (0.67; 95% CI, 0.25–1.75), aspiration pneumonia (0.95; 95% CI, 0.40–2.29), pneumonia (1.07; 95% CI, 0.62–1.86), or respiratory failure (0.75; 95% CI, 0.38–1.48) were not higher in patients prescribed a GLP1-RA. When comparing GLP1-RAs with opioids, crude relative risks were 0.42 (95% CI, 0.15–1.16) for aspiration, 0.60 (95% CI, 0.24–1.52) for aspiration pneumonia, 0.30 (95% CI, 0.19–0.49) for pneumonia, and 0.24 (95% CI, 0.13–0.45) for respiratory failure. These results were consistent across several sensitivity analyses.

Conclusions

GLP1-RA use is not associated with an increased risk of pulmonary complications after upper endoscopy compared with DPP4i use in patients with type 2 diabetes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胰高血糖素样肽-1 受体激动剂不会增加糖尿病患者上内镜检查时的吸入量。
背景和目的:胰高血糖素样肽-1受体激动剂(GLP1-RA)与更多胃内容物潴留有关,但目前还没有基于人群的对照研究来评估GLP1-RA在围手术期的潜在不良影响。我们旨在确定使用 GLP1-RA 的患者在上内镜检查后发生吸入和吸入相关并发症的风险是否会增加:我们利用一个全国性的商业行政索赔数据库,对 2005-2021 年间接受门诊上内镜检查的 18-64 岁 2 型糖尿病患者进行了一项回顾性队列研究。我们确定了 6,806,046 例独特的上内镜检查程序。我们比较了 GLP1-RA、二肽基肽酶 4 抑制剂 (DPP4i) 和慢性阿片类药物使用者在上内镜检查后 14 天内吸入和相关肺部不良事件的索赔情况。我们对年龄、性别、夏尔森综合症评分、基础呼吸系统疾病和胃痉挛进行了调整:我们发现,上内镜检查后发生肺部不良反应的情况很少见,每 10,000 例手术中发生 6-25 例。在比较 GLP1-RA 和 DPP4i 时,处方 GLP1-RA 的患者发生吸入(0.67 95%CI 0.25,1.75)、吸入性肺炎(0.95 95%CI 0.40,2.29)、肺炎(1.07 95%CI 0.62,1.86)或呼吸衰竭(0.75 95%CI 0.38,1.48)的粗相对风险并不高。如果将 GLP1-RA 与阿片类药物进行比较,吸入的粗相对风险(95%CI)为 0.42(0.15,1.16),吸入性肺炎为 0.60(0.24,1.52),肺炎为 0.30(0.19,0.49),呼吸衰竭为 0.24(0.13,0.45)。这些结果在多项敏感性分析中都是一致的:结论:与使用 DPP4i 相比,2 型糖尿病患者使用 GLP1-RA 与上内镜检查后肺部并发症风险增加无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Effects of Slightly Acidic Electrolyzed Water on the Quality of Fresh-Cut Apple.
IF 5.2 2区 农林科学FoodsPub Date : 2022-12-22 DOI: 10.3390/foods12010039
Qing Gao, Ziyi Yang, Baoliang Bi, Jinsong He
Disinfection efficacy of slightly acidic electrolyzed water on marine plankton
IF 0 Applied ResearchPub Date : 2023-09-02 DOI: 10.1002/appl.202300049
Midori Kurahashi, Masaki Suzuki, Angelica Naka
来源期刊
CiteScore
16.90
自引率
4.80%
发文量
903
审稿时长
22 days
期刊介绍: Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.
期刊最新文献
AGA Clinical Practice Update on Sclerosing Mesenteritis: Commentary. Table of Contents Front Cover Editorial Board Correction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1